Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?

KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.

Is Football Safe for Kids?

Several young football players died while playing the sport so far this year, raising the perpetual question of whether football is safe for kids. Seven

September 11, 2024

Up and down the ladder: The latest comings and goings

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s

January 19, 2024

Antiverse raises £3.5 M ($4.6 M) to advance generative AI antibody design platform

Antiverse, a techbio company designing antibodies for challenging targets, today announced it has added £3.5 M ($4.6 M) to its seed funding.

October 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.